This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical considerations for optimizing the safety and efficacy of sustained delivery, with a specific focus on the PDS surgical implantation and refill-exchange procedures. Through case-based discussions, learners will evaluate patient-specific characteristics to determine the appropriate implementation of sustained delivery platforms, considering factors such as treatment history, ocular comorbidities, and individual patient needs to select optimal treatment approaches for neovascular AMD and DME.

Target Audience:

Retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME.

Learning Objectives:

• Appraise the latest data regarding the safety and efficacy of sustained delivery platforms for retinal diseases 
• Identify technical considerations to optimize the safety and efficacy of sustained delivery therapies for retinal diseases 
• Evaluate patient-specific characteristics when considering implementation of sustained delivery platforms for retinal diseases

This podcast, Part 3 of a 3-part series on thyroid eye disease (TED), examines the multidisciplinary management of TED with a focus on teprotumumab-associated adverse effects. Through expert discussions and case-based examples, listeners will learn best practices for managing hyperglycemia, hearing changes, and other potential complications. The session outlines the essential role of primary eye care professionals in comanaging TED, from early recognition to educating patients and coordinating care with specialists. Clinicians will be equipped to apply collaborative strategies to optimize outcomes for TED patients.

This podcast, Part 2 of a 3-part series on thyroid eye disease (TED), provides an in-depth discussion of treatment strategies, focusing on current medical and surgical options as well as emerging therapies. Faculty review clinical data on teprotumumab, the only FDA-approved agent for TED. Listeners will also be introduced to clinical data on treatments including glucocorticoids, orbital radiation, rituximab, and tocilizumab and learn how to select appropriate therapies across a spectrum of disease activity and duration.

This podcast, Part 1 of a 3-part series on thyroid eye disease (TED), explores the clinical features of both active and chronic disease, providing a foundation for understanding how to effectively diagnose and manage this condition. Through expert discussions, the faculty review key diagnostic tools and clinical signs, offering insights into the spectrum of TED activity and duration. Listeners will also gain guidance on selecting appropriate treatments tailored to varying stages of disease, preparing them to optimize care for patients with TED.

In part 2 of our podcast series on geographic atrophy, Dr. Lejla Vajzovic and Dr. Arshad Khanani will do a deep dive into current treatment options to optimize patient outcomes. Listeners will be enabled to develop treatment plans for patients with geographic atrophy through a review of clinical study data, case scenarios, and real-world cases. This comprehensive session will empower listeners to confidently assess and manage geographic atrophy in their practice.

Geographic atrophy is a growing healthcare concern for retina specialists caring for an aging population. In the first part of this podcast series titled, Improving Outcomes in Patients with Geographic Atrophy, our experts, Dr. Arshad Khanani and Dr. Lejla Vajzovic, will educate listeners on the disease epidemiology, pathophysiology, and relevant clinical features of GA on imaging. The discussion will include didactics presented by our experts and real-world case studies.

Activity Description and Purpose
Demodex are ectoparasites that inhabit human hair follicles, including those on the face and eyelashes. Large infestations can cause Demodex blepharitis, a condition that has been associated with dry eye, meibomian gland dysfunction, and rosacea. Until recently, there were no US Food and Drug Administration–approved treatments for Demodex blepharitis, and off-label treatments were not reliably effective. This podcast covers the diagnosis and treatment of Demodex, including the recently approved treatment lotilaner, 0.25%.

Target Audience
This educational activity is intended for optometrists.

Learning Objectives
After completing this activity, participants will be better able to:

• Review best practices in the diagnosis of Demodex blepharitis
• Develop individualized treatment plans for patients with Demodex blepharitis

For more information or to view the webcast, please visit www.courses.mededicus.com

Activity Description and Purpose

This educational activity explores the advancements in geographic atrophy (GA) treatment options, focusing on clinical science data and real-world clinical presentations. Participants will gain insights into the latest US Food and Drug Administration–approved treatments, their mechanisms of action, clinical trial results, and patient safety considerations. Additionally, the educational activity emphasizes application in clinical practice via case examples, effective patient counseling techniques, and referral strategies to enhance patient outcomes and quality of life. This CME/CE activity is designed to enhance clinical competence and improve patient care in the management of GA. The desired results of this educational activity are for comprehensive ophthalmologists and optometrists to enhance their knowledge of the prevalence and pathophysiology of GA and new treatment options and to improve their competence in identifying and managing patients with GA.

Target Audience

This educational activity is intended for comprehensive ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

• Review clinical data for complement inhibitors used in the treatment of geographic atrophy
• Develop appropriate treatment plans for patients with geographic atrophy
• Employ appropriate counseling techniques for patients with geographic atrophy to facilitate referral

Activity Description and Purpose

This educational activity delves into the latest clinical practices for managing geographic atrophy (GA), a severe form of dry age-related macular degeneration. Learners will gain an in-depth understanding of epidemiologic indicators, diagnostic imaging, and the pathophysiology of GA related to the complement cascade. Learners will also gain a deeper understanding of GA by reviewing a case study along with the expert presenters. Designed to enhance clinical knowledge and improve patient outcomes, this CME/CE activity offers a comprehensive approach to understanding and diagnosing GA in clinical practice. The desired results of this educational activity are for comprehensive ophthalmologists and optometrists to enhance their knowledge of the prevalence and pathophysiology of GA and new treatment options and to improve their competence in identifying and managing patients with GA.

Target Audience

This educational activity is intended for comprehensive ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

• Recognize epidemiologic indicators of patients at risk for geographic atrophy 
• Review the clinically relevant features of geographic atrophy on imaging
• Describe the pathophysiology of geographic atrophy related to the complement cascade

Access the disclosures, evaluation, and your CME credit via:
https://courses.mededicus.com/content/discussing-evaporative-dry-eye-incorporating-new-treatments-practice-cmece-podcast

This podcast with Dr. Ken Beckman and Dr. Jaclyn Garlich delves into presentation and treatments of evaporative dry eye primarily caused by meibomian gland dysfunction (MGD). It explores the multifactorial nature of dry eye disease (DED), emphasizing the significance of MGD-driven DED, characterized by a deficient tear lipid layer. The discussion focuses on the latest treatment options, moving beyond traditional anti-inflammatory therapies to include newer topical solutions targeting evaporative loss. Real patient case studies contextualize these innovative approaches in the clinical management of DED.

After completing this activity, participants will be better able to:

• Incorporate diagnostic strategies that examine meibomian gland function in routine practice
• Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease